Profil
Michael Krams worked as the Vice President-Adaptive Trials at Wyeth LLC.
He then served as the Head-Quantitative Sciences at Janssen Pharmaceuticals, Inc. from 2013 to 2022.
Currently, he is the Chief Quantitative Medicine Officer at Exscientia Plc.
Dr. Krams holds a doctorate degree from Ludwig-Maximilians-Universität München.
Ehemalige bekannte Positionen von Michael Krams
| Unternehmen | Position | Ende |
|---|---|---|
| EXSCIENTIA PLC | Technik-/Wissenschafts-/F&E-Leiter | 06.06.2024 |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Corporate Officer/Principal | 01.02.2022 |
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products | Corporate Officer/Principal | - |
Ausbildung von Michael Krams
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products | Health Technology |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Health Technology |
Ludwig-Maximilians-Universität München
Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Exscientia Plc
Exscientia Plc Packaged SoftwareTechnology Services Function as an investment holding company whose subsidiaries provides artificial intelligence and machine learning services | Technology Services |
















